Recently, selonsertib (Ser), a selective inhibitor of Apoptosis Signal-regulated kinase-1 (ASK1), has attracted wide close attention for its anti-apoptosis and anti-inflammation effects in nonalcoholic steatohepatitis (NASH) treatment (Younossi et al., 2018). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.